Mizuho analyst Ann Hynes lowered the firm’s price target on Iqvia (IQV) to $190 from $210 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1 report.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Positive Outlook for IQVIA Holdings Driven by Resilient TAS, Strategic Capital Allocation, and R&D Strength
- Definitive Healthcare downgraded to Neutral from Buy at BTIG
- IQVIA Holdings: Strong Performance and Growth Potential Justify Buy Rating
- IQVIA Holdings: Strong Buy Rating Despite R&D Challenges and Valuation Opportunities
- Iqvia price target lowered to $185 from $255 at UBS